240 related articles for article (PubMed ID: 25858032)
1. GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases.
Roberts JL; Tavallai M; Nourbakhsh A; Fidanza A; Cruz-Luna T; Smith E; Siembida P; Plamondon P; Cycon KA; Doern CD; Booth L; Dent P
J Cell Physiol; 2015 Oct; 230(10):2552-78. PubMed ID: 25858032
[TBL] [Abstract][Full Text] [Related]
2. GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human disease.
Booth L; Roberts JL; Cash DR; Tavallai S; Jean S; Fidanza A; Cruz-Luna T; Siembiba P; Cycon KA; Cornelissen CN; Dent P
J Cell Physiol; 2015 Jul; 230(7):1661-76. PubMed ID: 25546329
[TBL] [Abstract][Full Text] [Related]
3. Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function.
Booth L; Shuch B; Albers T; Roberts JL; Tavallai M; Proniuk S; Zukiwski A; Wang D; Chen CS; Bottaro D; Ecroyd H; Lebedyeva IO; Dent P
Oncotarget; 2016 Mar; 7(11):12975-96. PubMed ID: 26887051
[TBL] [Abstract][Full Text] [Related]
4. Nexavar/Stivarga and viagra interact to kill tumor cells.
Tavallai M; Hamed HA; Roberts JL; Cruickshanks N; Chuckalovcak J; Poklepovic A; Booth L; Dent P
J Cell Physiol; 2015 Sep; 230(9):2281-98. PubMed ID: 25704960
[TBL] [Abstract][Full Text] [Related]
5. Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo.
Booth L; Albers T; Roberts JL; Tavallai M; Poklepovic A; Lebedyeva IO; Dent P
Oncotarget; 2016 Jun; 7(26):40398-40417. PubMed ID: 27259258
[TBL] [Abstract][Full Text] [Related]
6. Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma.
Canter RJ; Ames E; Mac S; Grossenbacher SK; Chen M; Li CS; Borys D; Smith RC; Tellez J; Sayers TJ; Monjazeb AM; Murphy WJ
BMC Cancer; 2014 Oct; 14():756. PubMed ID: 25301268
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
Miners JO; Chau N; Rowland A; Burns K; McKinnon RA; Mackenzie PI; Tucker GT; Knights KM; Kichenadasse G
Biochem Pharmacol; 2017 Apr; 129():85-95. PubMed ID: 28065859
[TBL] [Abstract][Full Text] [Related]
8. Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance.
Webb T; Carter J; Roberts JL; Poklepovic A; McGuire WP; Booth L; Dent P
Cancer Biol Ther; 2015; 16(11):1660-70. PubMed ID: 26417912
[TBL] [Abstract][Full Text] [Related]
9. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
Stacchiotti S; Tortoreto M; Baldi GG; Grignani G; Toss A; Badalamenti G; Cominetti D; Morosi C; Dei Tos AP; Festinese F; Fumagalli E; Provenzano S; Gronchi A; Pennacchioli E; Negri T; Dagrada GP; Spagnuolo RD; Pilotti S; Casali PG; Zaffaroni N
Eur J Cancer; 2014 Nov; 50(17):3021-8. PubMed ID: 25269954
[TBL] [Abstract][Full Text] [Related]
10. [Multikinase inhibitors as a new approach in neovascular age-related macular degeneration (AMD) treatment: in vitro safety evaluations of axitinib, pazopanib and sorafenib for intraocular use].
Thiele S; Liegl RG; König S; Siedlecki J; Langer J; Eibl K; Haritoglou C; Kampik A; Kernt M
Klin Monbl Augenheilkd; 2013 Mar; 230(3):247-54. PubMed ID: 23508753
[TBL] [Abstract][Full Text] [Related]
11. Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib.
Gotink KJ; Rovithi M; de Haas RR; Honeywell RJ; Dekker H; Poel D; Azijli K; Peters GJ; Broxterman HJ; Verheul HM
Cell Oncol (Dordr); 2015 Apr; 38(2):119-29. PubMed ID: 25665527
[TBL] [Abstract][Full Text] [Related]
12. Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats.
Yildiz C; Kacan T; Akkar OB; Karakus S; Kacan SB; Ozer H; Cetin A
Reprod Sci; 2015 Nov; 22(11):1445-51. PubMed ID: 25963915
[TBL] [Abstract][Full Text] [Related]
13. In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy.
Craveiro RB; Ehrhardt M; Holst MI; Pietsch T; Dilloo D
Oncotarget; 2014 Aug; 5(16):7149-61. PubMed ID: 25216529
[TBL] [Abstract][Full Text] [Related]
14. Biological evaluation of a novel sorafenib analogue, t-CUPM.
Wecksler AT; Hwang SH; Liu JY; Wettersten HI; Morisseau C; Wu J; Weiss RH; Hammock BD
Cancer Chemother Pharmacol; 2015 Jan; 75(1):161-71. PubMed ID: 25413440
[TBL] [Abstract][Full Text] [Related]
15. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Leung HW; Chan AL
Clin Ther; 2011 Jun; 33(6):708-16. PubMed ID: 21704235
[TBL] [Abstract][Full Text] [Related]
16. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
Yun SM; Jung KH; Lee H; Son MK; Seo JH; Yan HH; Park BH; Hong S; Hong SS
Cancer Lett; 2013 May; 331(2):250-61. PubMed ID: 23340175
[TBL] [Abstract][Full Text] [Related]
17. The Nonspecific Binding of Tyrosine Kinase Inhibitors to Human Liver Microsomes.
Burns K; Nair PC; Rowland A; Mackenzie PI; Knights KM; Miners JO
Drug Metab Dispos; 2015 Dec; 43(12):1934-7. PubMed ID: 26443648
[TBL] [Abstract][Full Text] [Related]
18. HSPA5/Dna K may be a useful target for human disease therapies.
Booth L; Roberts JL; Dent P
DNA Cell Biol; 2015 Mar; 34(3):153-8. PubMed ID: 25689303
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.
Kiprianova I; Remy J; Milosch N; Mohrenz IV; Seifert V; Aigner A; Kögel D
Neoplasia; 2015 Jul; 17(7):564-73. PubMed ID: 26297434
[TBL] [Abstract][Full Text] [Related]
20. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.
López-Fauqued M; Gil R; Grueso J; Hernandez-Losa J; Pujol A; Moliné T; Recio JA
Int J Cancer; 2010 Apr; 126(7):1549-61. PubMed ID: 19810100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
